Vasomotor Symptoms as a sex hormone-dependent disorder in women and men

Inclusion Criteria

:
- Participant must be 18 to 60 years of age inclusive, at the time of signing the informed consent. 
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG), vital signs, respiratory rate and body temperature. 
- Body weight above or equal 50 kg and body mass index (BMI) within the range 18.0 and 30.0 kg/m^2(inclusive). 
- Male and female: 
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 
-- Male participants: Male participants of reproductive potential must agree to use a condom (with or without spermicide) when sexually active. This applies for the time period between the signing of the informed consent form (ICF) until 5 days after the last dose of study intervention. Female partners of childbearing potential of male participants do not need to follow special precautions. 
-- Female participants: Women of childbearing potential will have to use highly effective non-hormonal contraception when having sexual intercourse with a male partner from signing the ICF until 5 days after last dose of the study drug. Women of non-childbearing potential are not required to use contraception.

Exclusion Criteria

- Any clinically relevant abnormal findings in medical history and physical examination which in the opinion of the investigators, may put the participant at risk because of his/her participation in the trial or provide difficulties in interpreting the trial data.
- Known hypersensitivity to the study interventions (active substances, or excipients of the preparations), or structurally related drugs to CBZ (carbamazepine, e.g. tricyclic antidepressants).
- History of bone marrow depression. 
- History of clinically hepatic disorders including hepatic porphyria (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda). 
- History or family history of severe cutaneous reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome.
- Human leukocyte antigen A (HLA-A) *31:01 or human leukocyte antigen B (HLA-B) *15:02 allele.
- History of myotonic dystrophy. 
- History of clinically relevant psychiatric disorder, including psychosis or latent psychosis.
- History of epileptic seizures. 
- History of clinically relevant depression, or suicidal ideation or behavior.